Partial Breast Irradiation With Multi-Catheter Brachytherapy for pT1-2pN0 Breast Cancer After Breast Conserving Surgery

NCT ID: NCT00392184

Last Updated: 2015-06-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

274 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-11-30

Study Completion Date

2010-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether accelerated partial breast irradiation (APBI) with multi-catheter brachytherapy is safe and effective.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

APBI

Accelerated Partial Breast Irradiation with interstitial Brachytherapy

Group Type EXPERIMENTAL

Accelerated partial breast irradiation

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Accelerated partial breast irradiation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pT1/2 (≤ 3 cm)
* pN0 or pN1 mi
* M0 and no contralateral BC
* Clear margins (≥ 2 mm)
* Age ≥ 35 years
* ER and/or PR positive

Exclusion Criteria

* Multifocality or Multicentricity
* EIC
* Lymphovascular invasion
* Poorly differentiated tumors
* Diffuse microcalcifications
Minimum Eligible Age

35 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Erlangen-Nürnberg Medical School

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vratislav Strnad, MD

Role: STUDY_CHAIR

University Hospital Erlangen, Germany

Oliver J Ott, MD

Role: STUDY_DIRECTOR

University Hospital Erlangen, Germany

Guido Hildebrandt, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital Leipzig, Germany

Richard Pötter, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital AKH Vienna, Austria

Joe Hammer, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Barmherzige Schwestern Linz, Austria

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Barmherzige Schwestern Linz

Linz, , Austria

Site Status

University Hospital AKH Vienna

Vienna, , Austria

Site Status

University Hospital Erlangen

Erlangen, , Germany

Site Status

University Hospital Leipzig

Leipzig, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Germany

References

Explore related publications, articles, or registry entries linked to this study.

Ott OJ, Potter R, Hammer J, Hildebrandt G, Lotter M, Resch A, Pohls U, Beckmann MW, Sauer R, Strnad V. Accelerated partial breast irradiation with iridium-192 multicatheter PDR/HDR brachytherapy. Preliminary results of the German-Austrian multicenter trial. Strahlenther Onkol. 2004 Oct;180(10):642-9. doi: 10.1007/s00066-004-1294-2.

Reference Type RESULT
PMID: 15480513 (View on PubMed)

Strnad V, Ott O, Potter R, Hildebrandt G, Hammer J, Resch A, Lotter M, Ackermann S, Beckmann MW, Sauer R. Interstitial brachytherapy alone after breast conserving surgery: interim results of a German-Austrian multicenter phase II trial. Brachytherapy. 2004;3(3):115-9. doi: 10.1016/j.brachy.2004.08.003.

Reference Type RESULT
PMID: 15533801 (View on PubMed)

Ott OJ, Potter R, Hildebrandt G, Hammer J, Lotter M, Beckmann MW, Sauer R, Strnad V. [Partial breast irradiation for early breast cancer with favorable prognostic factors: 3-year results of the German-Austrian phase II-trial]. Rofo. 2005 Jul;177(7):962-7. doi: 10.1055/s-2005-858268. German.

Reference Type RESULT
PMID: 15973598 (View on PubMed)

Ott OJ, Hildebrandt G, Potter R, Hammer J, Hindemith M, Resch A, Spiegl K, Lotter M, Uter W, Kortmann RD, Schrauder M, Beckmann MW, Fietkau R, Strnad V. Accelerated partial breast irradiation with interstitial implants: risk factors associated with increased local recurrence. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1458-63. doi: 10.1016/j.ijrobp.2010.04.032. Epub 2010 Aug 2.

Reference Type DERIVED
PMID: 20675064 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

German-Austrian APBI Trial

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.